ClinicalTrials.gg
Active, not recruitingNCT04223856EV-302Updated May 29, 2026Results posted

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

A Phase 3 interventional study of Enfortumab vedotin and Pembrolizumab in Urothelial Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 260 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
886
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.

Read the detailed description

Japan PMDA has approved enfortumab vedotin (Padcev) for the treatment of advanced urothelial cancer. The study will continue as a post marketing study in Japan.

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care gemcitabine + platinum-containing chemotherapy, in subjects with previously untreated locally advanced or metastatic urothelial cancer.

Enfortumab vedotin may be administered for an unlimited number of cycles until a protocol defined reason for study discontinuation occurs. Pembrolizumab may be administered for a maximum of 35 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first. Cisplatin or carboplatin plus gemcitabine may be administered for a maximum of 6 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first.

02

Conditions studied

  • Urothelial Cancer

Keywords

  • Urothelial Cancer
  • Enfortumab vedotin
  • metastatic urothelial cancer
  • pembrolizumab
  • locally advanced urothelial cancer
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented, unresectable locally advanced or urothelial carcinoma
  • by investigator assessment according to v1.1

    • Participants with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy
  • Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:

    • Participants that received chemotherapy with recurrence >12 months from completion of therapy are permitted
    • Participants that received adjuvant chemotherapy following cystectomy with recurrence >12 months from completion of therapy are permitted
  • Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment
  • comprising muscle-invasive urothelial carcinoma or a biopsy of metastatic urothelial carcinoma must be provided for testing prior to randomization
  • (ECOG) Performance Status score of 0, 1, or 2
  • Adequate hematologic and organ function

Exclusion criteria

Exclusion Criteria:

  • Previously received enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADCs)
  • Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any , including earlier stage urothelial cancer (UC), defined as a inhibitor or PD-L1 inhibitor
  • Received prior treatment with an agent directed to another stimulatory or co inhibitory T-cell receptor
  • Received anti-cancer treatment with chemotherapy, biologics, or agents not otherwise prohibited by exclusion criterion 1-3 that is not completed 4 weeks prior to first dose of study treatment
  • Uncontrolled diabetes
  • Estimated of less than 12 weeks
  • Active central nervous system (CNS)
  • Ongoing toxicity associated with prior treatment that has not resolved to ≤ Grade 1 or returned to baseline
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted.
  • Known active , active , or (HIV) infection.
  • History of another invasive malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy
  • Documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction, or cardiac symptoms consistent with (NYHA) Class IV within 6 months prior to randomization
  • Receipt of radiotherapy within 2 weeks prior to randomization
  • Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
  • Known severe (≥ Grade 3) to any enfortumab vedotin contained in the drug formulation of enfortumab vedotin
  • Active keratitis or corneal ulcerations
  • History of disease that has required systemic treatment in the past 2 years
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplant
  • Received a within 30 days prior to randomization
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
886 participants (actual)

Study arms

  • Experimental
    Arm A

    Enfortumab vedotin + pembrolizumab

    Drug: Enfortumab vedotin · Drug: Pembrolizumab

  • Active comparator
    Arm B

    Gemcitabine + cisplatin or carboplatin

    Drug: Cisplatin · Drug: Carboplatin · Drug: Gemcitabine

Interventions

  • Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle

    Also known as: ASG-22CE, ASG-22ME, PADCEV

  • IV infusion on Day 1 of every 3-week cycle

    Also known as: Keytruda

  • administered as IV infusion on Day 1 of each 3-week cycle

  • Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle

  • IV infusion on Days 1 and 8 of every 3 week cycle

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)

    PFS was defined as the time from date of randomization to first documentation of disease progression (PD), or to death due to any cause, whichever occurred first. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). PD could also be unequivocal progression of non-target lesions or the presence of unequivocal new lesions. Kaplan-Meier method was used for analysis.

    Time frame: From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum exposure to treatment was up to 39.2 months)

  2. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. In the absence of death, OS was censored at the date the participant was last known to be alive. Kaplan-Meier method was used for analysis.

    Time frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum exposure to treatment was up to 39.2 months)

Secondary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR) Per RECIST v1.1 by BICR

    ORR as per RECIST v1.1 by BICR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) CR was defined as disappearance of all lesions including non-target lesions (not just target lesions). Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30 percent \[%\] decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

    Time frame: From first dose till CR/PR or PD or death, whichever occurred first (maximum up to approximately 7.4 years)

  2. Time to Pain Progression (TTPP)

    TTPP was defined as the time from the date of randomization to date of pain progression. Pain progression was defined as a participant reporting either of the following, whichever came first: 1) Increase of 2 or more points from baseline on Brief Pain Inventory - Short Form (BPI-SF) Question 3 (i.e., pain at its worst in the last 24 hours, score range 0 to 10 with higher scores associated with higher pain levels) maintained for at least two consecutive assessments. 2) Initiation of new opioid medication from baseline for pain with usage maintained for at least two consecutive assessments as recorded in BPI-SF Question 7 (i.e., What medications received for pain).

    Time frame: From the date of randomization to date of pain progression (maximum up to approximately 7.4 years)

  3. Change From Baseline in Worst Pain Using BPI-SF at Week 26

    Brief Pain Inventory (BPI-SF) was defined as summary of the worst, least, and average pain experienced in the last 24 hours as well as pain right now and number of pain locations were provided for each treatment arm. BPI-sf worst pain measured the severity of pain based on the pain at its worst in the last 24 hours, score range 0 to 10 with higher scores associated with higher pain levels.

    Time frame: Baseline, Week 26

  4. PFS Per RECIST v1.1 by Investigator Assessment

    PFS as per RECIST v1.1 by investigator was defined as the time from date of randomization to first documentation of PD, or to death due to any cause, whichever comes first. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD could also be unequivocal progression of non-target lesions or the presence of unequivocal new lesions.

    Time frame: From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 7.4 years)

  5. ORR Per RECIST v1.1 by Investigator Assessment

    ORR as per RECIST v1.1 by investigator was defined as the percentage of participants with confirmed CR or PR. CR was defined as disappearance of all lesions including non-target lesions (not just target lesions). Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

    Time frame: From first dose till CR/PR or PD or death, whichever occurred first (maximum up to approximately 7.4 years)

  6. Duration of Response (DOR) Per RECIST v1.1 by BICR

    DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to the first documented PD per RECIST v1.1 per BICR or death from any cause, whichever occurs first. DOR will only include subjects with a confirmed response (CR or PR per RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From the date of first documented response of CR or PR to the first documented disease progression or to death from any cause, whichever occurred first (maximum up to approximately 7.4 years)

  7. DOR Per RECIST v1.1 by Investigator Assessment

    DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to the first documented PD per RECIST v1.1 per investigator or death from any cause, whichever occurs first. DOR will only include subjects with a confirmed response (CR or PR per RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

    Time frame: From the date of first documented response of CR or PR to the first documented disease progression or to death from any cause, whichever occurred first (maximum up to approximately 7.4 years)

  8. Disease Control Rate (DCR) Per RECIST v1.1 by BICR

    DCR by BICR was defined as the percentage of participants with confirmed response (CR or PR), or SD (or non-CR/non-PD), per RECIST v1.1. Subjects who have no post-baseline response assessments will be considered as non-responders for calculating the DCR. Only response assessments before the first documented PD or subsequent anticancer therapies were considered. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. SD was defined as a change in tumor size that is neither radiological response (\>30% shrinkage) nor progression (\>20% growth).

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to approximately 7.4 years)

  9. DCR Per RECIST v1.1 by Investigator Assessment

    DCR by BICR was defined as the percentage of participants with confirmed response (CR or PR), or SD (or non-CR/non-PD), per RECIST v1.1. Subjects who have no post-baseline response assessments will be considered as non-responders for calculating the DCR. Only response assessments before the first documented PD or subsequent anticancer therapies were considered. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. SD was defined as a change in tumor size that is neither radiological response (\>30% shrinkage) nor progression (\>20% growth).

    Time frame: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to approximately 7.4 years)

  10. Mean Scores in Patient Reported Outcome (PRO) Assessment Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)

    The EQ-5D-5L is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (EQ-5D-5L User Guide, 2019). Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).

    Time frame: End of study (approximately up to 7.4 years)

  11. Change From Baseline in PRO Assessment Measured by the EQ-5D-5L

    The EQ-5D-5L is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (EQ-5D-5L User Guide, 2019). Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).

    Time frame: Baseline, End of study (approximately up to 7.4 years)

  12. Mean Scores in PRO Assessment Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms.

    Time frame: End of study (approximately up to 7.4 years)

  13. Change From Baseline in PRO Assessment Measured by EORTC QLQ-C30

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

    Time frame: Baseline, End of study (approximately up to 7.4 years)

  14. Number of Participants With Treatment Emergent Adverse Events Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

  15. Number of Participants With Serious TEAE

    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

  16. Number of Participants With Grade 3-5 TEAE

    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per common terminology criteria for adverse events (CTCAE) version 4, Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE.

    Time frame: From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

  17. Number of Participants Related to Treatment AEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment relatedness was assessed by the investigator.

    Time frame: From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

  18. Number of Participants With Laboratory Abnormalities

    Laboratory abnormalities included Hematology and Serum Chemistry. In Hematology (increased : hemoglobin, lymphocytes, leukocytes, and decreased : hemoglobin, lymphocytes, neutrophils, platelets and leukocytes) and In serum chemistry (increased in : alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, calcium corrected for albumin, creatinine, glucose (non-fasting), potassium, sodium, and decreased in albumin, calcium corrected for albumin, glucose (non-fasting), potassium, phosphate and sodium).

    Time frame: From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

  19. Number of Participants With Treatment Discontinuation Rate Due to AEs

    Time frame: During study (approximately up to 7.4 years)

07

Results

Posted Sep 27, 2024

Participant flow

Participants with untreated locally advanced or metastatic urothelial cancer (UC) were enrolled in the study.

Participant flow — Overall Study
MilestoneEnfortumab Vedotin + PembrolizumabStandard of Care
Started442444
Treated440433
Completed8244
Not completed434200
Withdrew: Progressive disease15373
Withdrew: Adverse event9762
Withdrew: Physician decision928
Withdrew: Withdrawal by subject2224
Withdrew: Other72
Withdrew: Randomized but not treated211
Withdrew: On-treatment1440

Outcome measures

PrimaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)

PFS was defined as the time from date of randomization to first documentation of disease progression (PD), or to death due to any cause, whichever occurred first. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). PD could also be unequivocal progression of non-target lesions or the presence of unequivocal new lesions. Kaplan-Meier method was used for analysis.

Time frame:
From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum exposure to treatment was up to 39.2 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)
MonthsEnfortumab Vedotin + PembrolizumabStandard of Care
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)12.5 (10.4 to 16.6)6.3 (6.2 to 6.5)
Statistical analysis
  • Enfortumab Vedotin + Pembrolizumab vs Standard of Care · Log Rank · p = <0.00001 (P value was calculated using stratified log-rank test. The p-value threshold for statistical significance is 0.005.) · Hazard ratio (hr): 0.450 · 95% CI 0.377 to 0.538HR was calculated using stratified Cox proportional hazards model.
PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. In the absence of death, OS was censored at the date the participant was last known to be alive. Kaplan-Meier method was used for analysis.

Time frame:
From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum exposure to treatment was up to 39.2 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsEnfortumab Vedotin + PembrolizumabStandard of Care
Overall Survival (OS)31.5 (25.4 to NA)16.1 (13.9 to 18.3)
Statistical analysis
  • Enfortumab Vedotin + Pembrolizumab vs Standard of Care · Log Rank · p = <0.00001 · Hazard ratio (hr): 0.468 · 95% CI 0.376 to 0.582HR was calculated using stratified Cox proportional hazards model.
SecondaryPercentage of Participants With Objective Response Rate (ORR) Per RECIST v1.1 by BICR

ORR as per RECIST v1.1 by BICR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) CR was defined as disappearance of all lesions including non-target lesions (not just target lesions). Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30 percent \[%\] decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

Time frame:
From first dose till CR/PR or PD or death, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryTime to Pain Progression (TTPP)

TTPP was defined as the time from the date of randomization to date of pain progression. Pain progression was defined as a participant reporting either of the following, whichever came first: 1) Increase of 2 or more points from baseline on Brief Pain Inventory - Short Form (BPI-SF) Question 3 (i.e., pain at its worst in the last 24 hours, score range 0 to 10 with higher scores associated with higher pain levels) maintained for at least two consecutive assessments. 2) Initiation of new opioid medication from baseline for pain with usage maintained for at least two consecutive assessments as recorded in BPI-SF Question 7 (i.e., What medications received for pain).

Time frame:
From the date of randomization to date of pain progression (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Worst Pain Using BPI-SF at Week 26

Brief Pain Inventory (BPI-SF) was defined as summary of the worst, least, and average pain experienced in the last 24 hours as well as pain right now and number of pain locations were provided for each treatment arm. BPI-sf worst pain measured the severity of pain based on the pain at its worst in the last 24 hours, score range 0 to 10 with higher scores associated with higher pain levels.

Time frame:
Baseline, Week 26

Results for this outcome have not been posted.

SecondaryPFS Per RECIST v1.1 by Investigator Assessment

PFS as per RECIST v1.1 by investigator was defined as the time from date of randomization to first documentation of PD, or to death due to any cause, whichever comes first. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD could also be unequivocal progression of non-target lesions or the presence of unequivocal new lesions.

Time frame:
From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryORR Per RECIST v1.1 by Investigator Assessment

ORR as per RECIST v1.1 by investigator was defined as the percentage of participants with confirmed CR or PR. CR was defined as disappearance of all lesions including non-target lesions (not just target lesions). Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

Time frame:
From first dose till CR/PR or PD or death, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per RECIST v1.1 by BICR

DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to the first documented PD per RECIST v1.1 per BICR or death from any cause, whichever occurs first. DOR will only include subjects with a confirmed response (CR or PR per RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From the date of first documented response of CR or PR to the first documented disease progression or to death from any cause, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryDOR Per RECIST v1.1 by Investigator Assessment

DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to the first documented PD per RECIST v1.1 per investigator or death from any cause, whichever occurs first. DOR will only include subjects with a confirmed response (CR or PR per RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response.

Time frame:
From the date of first documented response of CR or PR to the first documented disease progression or to death from any cause, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR) Per RECIST v1.1 by BICR

DCR by BICR was defined as the percentage of participants with confirmed response (CR or PR), or SD (or non-CR/non-PD), per RECIST v1.1. Subjects who have no post-baseline response assessments will be considered as non-responders for calculating the DCR. Only response assessments before the first documented PD or subsequent anticancer therapies were considered. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. SD was defined as a change in tumor size that is neither radiological response (\>30% shrinkage) nor progression (\>20% growth).

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryDCR Per RECIST v1.1 by Investigator Assessment

DCR by BICR was defined as the percentage of participants with confirmed response (CR or PR), or SD (or non-CR/non-PD), per RECIST v1.1. Subjects who have no post-baseline response assessments will be considered as non-responders for calculating the DCR. Only response assessments before the first documented PD or subsequent anticancer therapies were considered. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to\<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For a response to be considered as confirmed, the subsequent response needs to be at least 4 weeks after the initial response. SD was defined as a change in tumor size that is neither radiological response (\>30% shrinkage) nor progression (\>20% growth).

Time frame:
From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to approximately 7.4 years)

Results for this outcome have not been posted.

SecondaryMean Scores in Patient Reported Outcome (PRO) Assessment Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)

The EQ-5D-5L is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (EQ-5D-5L User Guide, 2019). Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).

Time frame:
End of study (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in PRO Assessment Measured by the EQ-5D-5L

The EQ-5D-5L is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (EQ-5D-5L User Guide, 2019). Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).

Time frame:
Baseline, End of study (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryMean Scores in PRO Assessment Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms.

Time frame:
End of study (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in PRO Assessment Measured by EORTC QLQ-C30

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

Time frame:
Baseline, End of study (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Serious TEAE

SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Grade 3-5 TEAE

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per common terminology criteria for adverse events (CTCAE) version 4, Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE.

Time frame:
From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants Related to Treatment AEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment relatedness was assessed by the investigator.

Time frame:
From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory abnormalities included Hematology and Serum Chemistry. In Hematology (increased : hemoglobin, lymphocytes, leukocytes, and decreased : hemoglobin, lymphocytes, neutrophils, platelets and leukocytes) and In serum chemistry (increased in : alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, calcium corrected for albumin, creatinine, glucose (non-fasting), potassium, sodium, and decreased in albumin, calcium corrected for albumin, glucose (non-fasting), potassium, phosphate and sodium).

Time frame:
From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Discontinuation Rate Due to AEs
Time frame:
During study (approximately up to 7.4 years)

Results for this outcome have not been posted.

Adverse events

Collected over From start of treatment up to 37 days after last dose of study drug (up to 40 months 9 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enfortumab Vedotin + Pembrolizumab133/442 (30.1%)220/440 (50%)435/440 (98.9%)
Standard of Care226/444 (50.9%)169/433 (39%)418/433 (96.5%)
Most frequent serious events
Showing 10 of 245
Most frequent serious events
EventEnfortumab Vedotin + PembrolizumabStandard of Care
Urinary tract infectionInfections and infestations16/44031/433
Acute kidney injuryRenal and urinary disorders23/44011/433
AnaemiaBlood and lymphatic system disorders3/44017/433
DiarrhoeaGastrointestinal disorders14/4402/433
ThrombocytopeniaBlood and lymphatic system disorders0/44013/433
Febrile neutropeniaBlood and lymphatic system disorders4/44012/433
PyrexiaGeneral disorders9/44010/433
HaematuriaRenal and urinary disorders7/44010/433
PneumoniaInfections and infestations10/4405/433
PneumonitisRespiratory, thoracic and mediastinal disorders9/4400/433
Most frequent other events
Showing 10 of 65
Most frequent other events
EventEnfortumab Vedotin + PembrolizumabStandard of Care
AnaemiaBlood and lymphatic system disorders106/440255/433
Peripheral sensory neuropathyNervous system disorders228/44044/433
PruritusSkin and subcutaneous tissue disorders182/44029/433
NeutropeniaBlood and lymphatic system disorders43/440178/433
NauseaGastrointestinal disorders114/440176/433
FatigueGeneral disorders152/440167/433
DiarrhoeaGastrointestinal disorders161/44067/433
AlopeciaSkin and subcutaneous tissue disorders152/44034/433
ThrombocytopeniaBlood and lymphatic system disorders19/440147/433
ConstipationGastrointestinal disorders116/440146/433

Baseline characteristics

Intent-to-Treat (ITT) analysis set include all randomized participants. Participants were analyzed according to the treatment arm assigned at randomization regardless of the actual treatment received.

Age, Continuous
Age, Continuous(Years)Enfortumab Vedotin + PembrolizumabStandard of CareTotal
Mean67.9 ± 9.168.0 ± 9.467.9 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Enfortumab Vedotin + PembrolizumabStandard of CareTotal
Female98108206
Male344336680
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enfortumab Vedotin + PembrolizumabStandard of CareTotal
Hispanic or Latino5252104
Not Hispanic or Latino359343702
Unknown or Not Reported314980
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Enfortumab Vedotin + PembrolizumabStandard of CareTotal
Race — American Indian or Alaska Native224
Race — Asian9992191
Race — Black or African American3710
Race — Native Hawaiian or Other Pacific Islander011
Race — White308290598
Race — Other314
Race — Multiple044
Race — Unknown51015
Race — Not Reported223759
08

Study locations

260 sites
  • Ironwood Cancer & Research Centers - Chandler
    Chandler, Arizona 85224, United States
  • Arizona Oncology Associates PD - HOPE
    Tucson, Arizona 85710, United States
  • Providence St Joseph Medical Center
    Burbank, California 91505, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California Los Angeles Medical Center
    Los Angeles, California 90095, United States
  • University of California Irvine - Newport
    Orange, California 92868, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • University of Colorado Hospital / University of Colorado
    Aurora, Colorado 80045, United States
  • Cancer Centers of Colorado - Denver
    Denver, Colorado 80218, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Eastern CT Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • Lombardi Cancer Center / Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Winship Cancer Institute / Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Georgia Cancer Specialists / Northside Hospital Cancer Institute
    Marietta, Georgia 30060, United States
  • Louisiana State University/ East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
  • Maine Health Cancer Care
    Biddeford, Maine 04046, United States
  • Johns Hopkins Medical Center
    Baltimore, Maryland 21231, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New Mexico Cancer Center
    Albuquerque, New Mexico 87109, United States
  • New York University (NYU) Cancer Institute
    New York, New York 10016, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Vidant Medical Center
    Greenville, North Carolina 27834, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • Hillman Cancer Center / University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Saint Francis Hospital / Bon Secours - South Carolina
    Greenville, South Carolina 29607, United States
  • West Cancer Center & Research Institute
    Germantown, Tennessee 38138, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • UT Health East Texas Hope Cancer Center
    Tyler, Texas 75701, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109, United States
  • Site AR54008
    Buenos Aire, C1019ABS, Argentina
  • Site AR54011
    CABA, C1426ANZ, Argentina
  • Site AR54005
    Córdoba, X5004FHP, Argentina
  • Site AR54006
    La Rioja, 5300, Argentina
  • Site AR54004
    Mendoza, M5500AYB, Argentina
  • Site AR54001
    Rosario, 2000, Argentina
  • Site AR54002
    San Miguel, T400GTB, Argentina
  • Site AR54012
    San Miguel de Tucumán, T4000IAK, Argentina
  • Site AR54003
    Viedma, 8500, Argentina
  • Site AU61003
    Box Hill, 3128, Australia
  • Site AUS61001
    Douglas, 4814, Australia
  • Site AUS61004
    Heidelberg, 3084, Australia
  • Site AUS61002
    Macquarie Park, 2109, Australia
  • Site AUS61006
    South Australia, 5112, Australia
  • Site AU61005
    South Brisbane, 4101, Australia
  • Site BE32003
    Brussels, 1200, Belgium
  • Site BE32002
    Ghent, 9000, Belgium
  • Site BE32001
    Liège, 4000, Belgium
  • Site BE32007
    Lueven, 3000, Belgium
  • Site BE32006
    Roeselare, 8800, Belgium
  • Site CA11004
    Calgary, Alberta T2N 4N2, Canada
  • Site CA11003
    Edmonton, Alberta T6G 1Z2, Canada
  • Site CA11006
    Vancouver, British Columbia V5Z 4E6, Canada
  • Site CA11002
    Hamilton, Ontario L8V 1C3, Canada
  • Site CA11009
    London, Ontario N6A 5A5, Canada
  • Site CA11011
    Oshawa, Ontario L1G 2B9, Canada
  • Site CA11012
    Toronto, Ontario M4N 3M5, Canada
  • Site CA11005
    Toronto, Ontario M5G 2M9, Canada
  • Site CA11010
    Montreal, Quebec H2X 0A9, Canada
  • Site CA11001
    Montreal, Quebec H3T 1E2, Canada
  • Site CA11008
    Québec, G1R 2J6, Canada
  • Site CN86009
    Beijing, 100021, China
  • Site CN86001
    Beijing, 100036, China
  • Site CN86004
    Beijing, 100050, China
  • Site CN86005
    Beijing, 100191, China
  • Site CN86015
    Bengbu, 233000, China
  • Site CN86003
    Changchun, 130021, China
  • Site CN86006
    Changsha, 410013, China
  • Site CN86016
    Changsha, 410013, China
  • Site CN86010
    Chengdu, 610041, China
  • Site CN86024
    Chongqing, 400030, China
  • Site CN86007
    Chongqing, 400038, China
  • Site CN86028
    Fuzhou, 350005, China
  • Site CN86002
    Guangzhou, 510120, China
  • Site CN86020
    Gunagzhou, 510280, China
  • Site CN86018
    Hangzhou, 0571, China
  • Site CN86013
    Hangzhou, 310014, China
  • Site CN86022
    Hangzhou, 310016, China
  • Site CN86025
    Hefei, 400030, China
  • Site CN86027
    Jinan, 250021, China
  • Site CN86017
    Nanjing, 210008, China
  • Site CN86012
    Nanjing, 210029, China
  • Site CN86021
    Ningbo, 315016, China
  • Site CN86014
    Shanghai, 200040, China
  • Site CN86011
    Shenyang, 110022, China
  • Site CN86023
    Tianjin, 300052, China
  • Site CN86019
    Tianjin, 453000, China
  • Site CN86029
    Wenzhou, 325000, China
  • Site CN86008
    Wuhan, 430030, China
  • Site CN86030
    Xicheng District, 100034, China
  • Site CN86026
    Xuzhou, 221009, China
  • Site CZ42006
    Brno, 656 91, Czechia
  • Site CZ42001
    Hradec Králové, 500 05, Czechia
  • Site CZ42004
    Olomouc, 779 00, Czechia
  • Site CZ42005
    Praha 4-Krc, 140 59, Czechia
  • Site DK45001
    Aalborg, 9100, Denmark

Showing the first 100 of 260 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Flechon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T. How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. Future Oncol. 2026 Apr;22(9):1015-1029. doi: 10.1080/14796694.2026.2645984. Epub 2026 Apr 2. PubMed 41925239 ↗
  • Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T. Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma. Int J Clin Oncol. 2026 Mar;31(3):436-446. doi: 10.1007/s10147-025-02950-8. Epub 2026 Jan 21. PubMed 41563650 ↗
  • Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ. 2025 Dec;28(1):1779-1797. doi: 10.1080/13696998.2025.2567190. Epub 2025 Oct 14. PubMed 41039930 ↗
  • Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Flechon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2025 Jun;26(6):795-805. doi: 10.1016/S1470-2045(25)00158-5. PubMed 40449498 ↗
  • Niegisch G. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer. N Engl J Med. 2024 Mar 7;390(10):944-946. doi: 10.1056/NEJMe2400311. No abstract available. PubMed 38446680 ↗
  • Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gumus M, Mar N, Loriot Y, Flechon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. PubMed 38446675 ↗
  • Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 Jan 1;41(1):22-31. doi: 10.1200/JCO.22.01643. Epub 2022 Aug 30. PubMed 36041086 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Aug 2023, 40 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 10, 2020
StartActual
Mar 30, 2020
Primary completionActual
Aug 8, 2023
CompletionEst.
Mar 1, 2028
Results first posted
Sep 27, 2024
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04223856
Responsible party
Sponsor
First posted
Jan 10, 2020
Start date
Mar 30, 2020
Primary completion
Aug 8, 2023
Completion
Mar 1, 2028 (estimated)
Results posted
Sep 27, 2024
Last update
May 29, 2026

Study contacts

Zejing Wang, MD, PhD
study director · Seagen Inc.
John Lu, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enfortumab vedotin · Pembrolizumab

Start the discussion